Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’-Reference-Cited by-同舟云学术

Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’

Published:2016-06-07 Issue:9 Volume:18 Page:847-854
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Skow M. A.¹,Bergmann N. C.¹,Knop F. K.¹²

Affiliation:

1. Centre for Diabetes Research, Gentofte Hospital; University of Copenhagen; Hellerup Denmark

2. Department of Biomedical Sciences and NNF Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences; University of Copenhagen; Copenhagen Denmark

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12685/fullpdf

Reference62 articles.

1. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus;Nauck;J Clin Invest,1993

2. Gastric inhibitory polypeptide enhancement of the insulin effect on fatty acid incorporation into adipose tissue in the rat;Beck;Regul Pept,1983

3. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas;Pederson;Endocrinology,1978

4. Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists;Finan;Mol Cell Endocrinol,2015

5. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM;Sadry;Nat Rev Endocrinol,2013

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management;Life Sciences;2024-08

2. The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis;Diabetes, Metabolic Syndrome and Obesity;2024-02

3. Development and Validation of Simultaneous Quantitative Dissolution Analysis for the Two Active Pharmaceutical Ingredients in Dapagliflozin Propanediol Monohydrate-sitagliptin Phosphate Monohydrate Multi-layered Tablets;Current Pharmaceutical Analysis;2023-12

4. Use of IDegLira to Intensify, Simplify, and Increase Appropriateness of Type 2 Diabetes Therapy: A Real-Life Experience;Diabetes Therapy;2023-10-26

5. Molecular basis of signal transduction mediated by the human GIPR splice variants;Proceedings of the National Academy of Sciences;2023-10-04